The introduction of nicotinamide to be a nicotine replacement in e-cigarette and smokeless merchandise represents a significant regulatory problem to the FDA. Nicotinamide does not have nicotinic receptor agonist activity and is known to work as a sedative at significant dosages6. The claims made by Nicotine River, ECBlend, and various distributors